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Abstract
Purpose—Clinical trials have commenced to evaluate the feasibility of targeting malignant gliomas
with genetically engineered cytolytic T-cells (CTLs) delivered directly to the tumor bed in the central
nervous system (CNS). The objective of this study is to determine a suite of MRI measurements,
using an orthotopic xenograft murine model, that can non-invasively monitor immunologically-
mediated tumor regression and reactive changes in the surrounding brain parenchyma.
Experimental Design—Our pre-clinical therapeutic platform is based on CTL genetic
modification to express a membrane tethered IL13 cytokine chimeric T-cell antigen receptor. This
enables selective binding and signal transduction upon encountering the glioma restricted IL-13α2
receptor. We used MRI to visualize immune responses following adoptive transfer of IL13Rα2-
specific CD8+ CTL clones.
Results—Based on MRI measurements several phases following IL13Rα2-specific T-cell adoptive
transfer could be distinguished, all of which correlated well with glioblastoma regression confirmed
upon histology. The first detectable changes, 24 h post treatment, were significantly increased T2-
relaxation times and strongly enhanced signal on T1-weighted post-contrast images. In the next phase
the apparent diffusion coefficient (ADC) was significantly increased at 2 and 3 days post treatment.
In the last phase, at day 3 post IL13Rα2-specific T-cell injection, the volume of hyperintense signal
on T1-weighted post contrast image was significantly decreased, while ADC remained elevated.
Conclusions—The present study indicates the feasibility of MRI to visualize different phases of
immune response when IL13Rα2-specific CTLs are administered directly to the glioma tumor bed.
This will further the aim of better predicting clinical outcome following immunotherapy.
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INTRODUCTION
Immunotherapy of neoplastic and infectious disease is an area of intense investigation (1-4).
As novel immunotherapeutics are applied to clinical trials, the need for reliable non-invasive
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imaging correlates of treatment efficacy and toxicity are imperative for advancing the field.
Imaging methods, such as magnetic resonance imaging (MRI), can provide noninvasive
longitudinal assessment of a number of tumor characteristics and is a standard modality
available to the clinical research community. Measures of these characteristics can be used
qualitatively and quantitatively to better predict treatment outcome. Diffusion-weighted MRI
(DWI) has been used to evaluate therapeutic responses in a variety of animal tumor models
(5-10), and in human clinical studies (11-14). Significantly increased ADC, measured with
DWI, in the treated area correlated well with successful treatment and good prognosis, whereas
reduced or unchanged ADC correlated with poor treatment and prognosis (5-10). Disrupted
blood brain barrier (BBB) permeability is associated with glioblastoma progression, and can
be visualized as increased signal intensity on T1-weighted post contrast MRI (10,15-17). In
addition, T2-weighted MRI provides information about alterations in water mobility thought
to be associated with cell death, vasogenic edema and inflammation (18-20). Obtaining
multidimensional profiles of tumor response to treatment will significantly facilitate
quantitative assessment of treatment efficacy and increase understanding of the underlying
mechanism(s), particularly when tumor and therapy generate similar qualitative MRI findings.
Imaging of malignant gliomas presents a particularly challenging venue for imaging antitumor
immune responses. We have developed and applied to first-in-human clinical trials for
glioblastoma treatment (21,22) a cellular immunotherapy based approach using genetically
modified cytolytic T-cells (CTLs) engineered to target interleukin-13 α2 receptor (IL-13Rα2)
positive high-grade gliomas including glioblastoma multiforme. These CTLs are modified to
express a membrane bound IL-13 cytokine fused to ζ-chain (IL13 - zetakine). In vitro studies
have shown that activation of the chimeric zetakine receptor upon contact with IL13Rα2+
glioma cells is sufficient to trigger T-cell effector functions ultimately leading to cytolytic
destruction of tumor cells (21). A reliable biomarker that can facilitate visualization of
interactions between glioblastoma and zetakine expressing CTLs is needed to carefully
evaluate in vivo applications of this technology and to monitor treatment in the clinical setting.
In this work we explore combined T2-weighted, DWI and T1-weighted post contrast MRI in
order to determine a reliable suite of measures that correlate well with successful cytotoxic
action of zetakine expressing T-cells in a mouse model system. Our focus is on the earliest
detectable changes using MRI that prove to have good correlation with final glioblastoma
regression. Following successful lysis of glioblastoma cells by IL13Rα2 T-cells we expect an
increase in extracellular water content leading to increased water diffusibility due to decreased
cell density, and to an increase in transverse relaxation time (T2). Moreover, it is likely that
reversal of disrupted blood brain barrier can indicate successful destruction of glioblastoma
cells. We found that increased T2-relaxation times and strongly enhanced signal on T1-
weighted post contrast images were the first changes, which presented at one day post
IL13Rα2 T-cell intracranial injection (i.c.) that correlated well with successful treatment. An
increase in ADC (two and three days post) followed; and last was reduction of the volume of
hyperintense signal on T1-weighted post contrast image, three days following IL13Rα2 T-cell
i.c. injection.
METHODS
Cell Lines and Cultures
The human glioblastoma cell line U87 was obtained from the American Type Culture
Collection (Rockville, MD). Peripheral Blood Mononuclear Cells were obtained from healthy
donors participating in a City of Hope National Medical Center Institutional Review Board-
approved protocol. The cells were isolated by density gradient centrifugation over Ficoll-Paque
(Pharmacia Biotech, Piscataway, NJ). T-cell lines and clones were cultured in RPMI 1640 with
10% heat-inactivated fetal calf serum (FCS), 25 mmol/L HEPES-BSS, 2 mmol/L L-glutamine
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and 50 U/mL rhIL-2 (Chiron, Emeryville, CA). Human glioblastoma U87 cells were grown in
Dulbecco’s Modified Eagle Media supplemented with 10% heat-inactivated FCS, 25 mmol/L
HEPES-BSS and 2 mmol/L L-glutamine.
Electroporation of Human T-cells with IL-13 Zetakine cDNA
The IL-13 cDNA synthesis and modification was done according to previously published
methods (21). In short, a hygromycin phosphotransferase-HSV thymidine kinase (HyTK)
selection/suicide fusion gene under the control of cytomegalovirus immediate-early promoter
was inserted into a plasmid containing IL-13 zetakine. The activation of T cells with OKT3
followed by electroporation and subsequent selection in hygromycin/rhIL-2 has been described
in more detail previously (23). Cell surface expression of the IL-13-zetakine was assayed by
staining with a phycoerythrin-conjugated antihuman IL-13 monoclonal antibody (Becton
Dickinson, San Jose, CA) and an IL-13Rα2/hIgG1 chimera (R&D Systems, Minneapolis, MN)
detected with a fluorescein isothiocyanate-conjugated antihuman IgG1 monoclonal antibody
(Sigma, St. Louis, MO). The phenotype of primary T-cells was determined using fluorescein
isothiocyanate-conjugated anti-CD4, and anti-CD8 and anti-TCR α/β monoclonal antibodies
(Becton Dickinson, CA).
Orthotopic Glioma Xenograft Model
Male NOD-scid mice, 6-8 weeks old were used. Mice were anesthetized with intraperitoneal
(ip) ketamine/xylazine (132/8.8 mg/kg). The hair on the top of the head was shaved, and prior
to incision the head was scrubbed with betadine/alcohol. Mice were immobilized in the
stereotaxic restraint apparatus (Stoelting, Wood Dale, IL) and a 5 mm long skin incision was
made along the sagital suture. A burr hole was drilled into the skull, 2 mm lateral and 0.5 mm
anterior to the bregma, and animals were then transferred to the E15600 Lab Standard
Stereotaxic Instrument (Stoelting) for injections using 30-gauge 5 μL Hamilton syringe.
Injections were done using a motorized injector over 3 to 5 min. U87-ffLucZeo glioblastoma
cells (1 × 105 cells/ μl) were suspended in 2 μL, 1 × PBS (Irvine Scientific, Irvine, CA) and
injected bilaterally: 2 mm lateral and 0.5 mm anterior to Bregma; 1 μl was injected at 2.5 mm
depth from dura, and 1 μl at 2.25 mm depth from dura. Burr holes were sealed with bone-wax
(Ethicon, Inc., Summerfield NJ), and the incisions were closed with Nexaband veterinary glue.
To aid in post-surgical recovery, mice were placed on a heating pad and injected with 0.1 mg/
kg Buprenex (subcutaneously). All experiments involving the use of animals were performed
in accordance with protocols approved by the Animal Care and Use Committee of California
Institute of Technology.
Treatment groups
Eleven days following glioblastoma injection N=6 mice were stereotaxically injected with
IL-13 zetakine transfected T-cells (3 μl, 2 × 106 cells), N=5 mice were injected with non-
specific T-cells (3 μl, 2 × 106 cells), and N=5 mice were injected with PBS (2 μl total volume).
The stereotaxic injections were done with the identical coordinates as the original glioblastoma
cell injections, with the following exception: IL13Rα2-specific T-cells and non-specific T-
cells were injected 1 μL at 2.5 mm depth from dura, 1 μL at 2.35 mm from dura and 1 μL at
2.25 mm from dura.
Magnetic Resonance Imaging
MRI was performed on a 7.0 T Bruker Biospin system using a 2 cm birdcage coil, one day
prior (-1 day), and then at one, two and three days post (+1 day, +2 days and +3 days) T-cell/
PBS injection. Prior to imaging animals were anesthetized with isoflurane (4% induction,
maintenance with 1.5%). During the imaging rectal temperature and respiration were
monitored, and isoflurane levels were adjusted if breathing was below 20 BPM or above 40
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BPM. The body temperature was maintained between 35-37 °C, during imaging with a custom-
built heating solenoid around the body. Each animal was imaged with a T2-weighted multi-
echo spin echo sequence (five 0.5 mm thick slices, TR/TE=3000/10.6-148.4 ms, 14 echoes,
117×117 μm2 resolution, 4 averages) and diffusion-weighted imaging (five 0.5 mm-thick
slices, TR/TE=3000/29 ms, Δ=12 ms, δ=5 ms, with three b-value=0, 500 and 1000 s/mm2,
127×163 μm2 resolution, 2 averages). T1-weighted spin echo (nine 0.5 mm thick slices, TR/
TE=500/10.6 ms, 117×117 μm2 resolution and 8 averages) images were acquired following
intravenous (i.v.) injection of contrast agent (Magnevist, Berlex Laboratories, Wayne, NJ).
After imaging each mouse was recovered on a heating pad, and then returned to his cage.
Transverse relaxation time constants (T2), and ADC were calculated on a pixel-by-pixel basis
from the corresponding exponential fits using CCHIPS software (24). Values for the T2 and
ADC histograms were calculated using NIH ImageJ software. Post-contrast hyperintense
volumes present in T1-weighted images (T1-WI) were determined using an automated
segmentation routine, CCHIPS (24). In addition, for animals treated with IL13Rα2 T-cells the
analysis of signal intensity on T1-WI for one day following i.c. injection was done. Upon visual
inspection of T1-WI a strongly enhancing area was observed only in this treatment group one
day following i.c. injection. Signal intensity ratios were calculated as: mean signal intensity of
the ipsilateral glioblastoma divided by mean signal intensity of the contralateral glioblastoma;
mean signal intensity of the strongly enhancing area in the ipsilateral glioblastoma divided by
mean signal intensity of the contralateral glioblastoma; and mean signal intensity of the
strongly enhancing area in the ipsilateral glioblastoma divided by mean signal intensity of the
ipsilateral glioblastoma (leaving out the strongly enhancing part).
Brain Histology and Immunohistochemistry
Four days following T-cell/PBS injections all mice were anesthetized with pentobarbital (100
mg/kg, i.p.) and perfused transcardially with 4% paraformaldehyde. The brain tissue was post-
fixed overnight in 4% paraformaldehyde and then embedded in paraffin. 10-μm thick sections
were cut, deparaffinized and stained by a standard hematoxylin and eosin (H&E) technique.
In addition, adjacent slices were processed by heat-induced antigen retrieval procedure using
citric buffer (pH 6.0) and then incubated overnight with Mouse monoclonal anti-CD45 (Dako
Cytomation, Carpinteria, CA). Sections were processed using Dako EnVision+ systems
(peroxidase), with blocking step and secondary antibody dilutions per manufacturer’s
instructions (Dako Cytomation, Carpinteria, CA). Diaminobenzidine (DakoCytomation) was
used as a chromogen. Mayer’s hemotoxylin was used for counterstain.
Statistical Analysis
In order to proceed with parametric or non-parametric statistics, data were first confirmed to
be normally distributed. Tumor volumes, average T2 and ADC values within the ipsilateral
and contralateral tumor volumes before and after treatment were analyzed using ANOVA with
repeated measures. Holm-Sidak method was used for multiple pairwise comparison correction.
A p-value less then 0.05 was considered statistically significant. Sigma Stat 9.0 (Systat
Software Inc., San Hose CA) was used for ANOVA analysis. Histograms for T2 and ADC
values (generated from a single representative slide) prior to and at different days following
the same treatment were compared using two-sample Kolmogorov-Smirnov test (p-value less
then 0.001 was considered statistically significant). Systat 11.0 (Systat Software Inc., San Hose
CA) was used for two sample Kolmogorov-Smirnov test.
Lazovic et al. Page 4














Changes in transverse relaxation time (T2) following application of IL13Rα2 expressing T-
cells
Longitudinal magnetic resonance imaging was used to determine physiological effects
associated with IL13Rα2 T-cells, non-specific T-cells and PBS in a murine tumor model
system. Variations in the free water content across the tumor and tumor edema can be directly
correlated with changes in T2-relaxation time (20). Previously, elevated T2-relaxation times
were associated with an increase in extracellular water and decreased cell density (18). Here
we expect increased T2-relaxation time as a consequence of glioblastoma cell lysis.
Significantly increased T2-values (p<0.05) were present in the ipsilateral hemisphere of mice
treated with IL13Rα2 T-cells 1 day following the injection (Table 1). This effect is also evident
in increased signal on T2-weighted images (Fig. 1). In contrast, there was a significant decrease
in T2-relaxation time at the distal tumor site, represented by the contralateral tumor volume,
for this treatment group (Table 1). No significant differences were present in mice treated with
PBS or non-specific T-cells at any of the imaging times (Fig. 1, Table 1).
In order to examine the variation of T2-values across the tumor, histograms for different days
and treatments were calculated (Fig. 1 D-F). Prior to any tumor treatment, all groups had similar
T2-distributions (Fig 1 D-F) (Kolmogorov-Smirnov test, p>0.1). The earliest change in the
histogram distribution, a shift toward longer T2-relaxation times, occurred one day following
specific T-cells injections (Fig 1 D, Kolmogorov-Smirnov test, p<0.001). For the animals
treated with non-specific T-cells there was a significant change in the histogram distribution
(Kolmogorov-Smirnov, p<0.001) at two and three days following i.c. injections (Fig. 1 E). In
contrast to IL13Rα2 T-cell treatment, histograms shifted toward shorter T2-values with non-
specific T-cells. There was no significant difference in the histogram distribution for animals
treated with PBS at any day following the injection (Kolmogorov-Smirnov, p>0.001).
ADC-values changes following application of IL13Rα2 expressing T-cells
Changes in the ADC were used as an additional measurement to detect spatial variations in
water mobility and decreased cell density. Increased ADC-values are usually associated with
areas of more mobile water (such as extracellular water) and reduced cell density (due to
glioblastoma cell lysis) (25). There was no significant change in ADC-values in the first day
following any of the treatments. The ADC-values become significantly increased (p<0.05) in
the ipsilateral glioblastoma treated with IL13Rα2 T-cells at two days following injection (Fig.
2, Table 2), and remained significantly increased the following day (Fig. 2, Table 2). In contrast,
no significant increase in ADC-values was detectable in mice injected with PBS or non-specific
T-cells at any time point examined (Fig. 2, Table 2).
Histograms were used to evaluate and compare ADC-value distributions within the tumor
regions for different days and treatments. Prior to onset of any treatment, all ADC histograms
looked similar (Fig. 2 D-F). A significant shift in the ADC distribution toward higher ADC-
values occurred only at two and three days following IL13Rα2 T-cell injection (Smirnov-
Kolmogorov test, p<0.001). There was no significant change in the histogram distributions at
any day following PBS or non-specific T-cell injections (Fig. 2 E, F).
Changes in the volume of hyperintense signal on T1-weighted post contrast agent imaging
Increased blood-brain permeability is closely associated with glioblastoma infiltration and
progression (15). To investigate the changes in blood-brain barrier properties associated with
successful treatment, a series of T1-weighted post-contrast MR imaging studies were
performed prior to and at day one and three post treatment. Prior to any treatments there was
no significant difference in the volume of hyperintense signal among the various mouse groups
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(one-way ANOVA, p>0.3). A tendency toward increased volume of hyperintense signal was
noticed at day 1 post injection, independent of treatment group, (Fig. 3 A, B, C, D). A significant
decrease in the volume of hyperintense signal was found only 3 days post IL13Rα2 T-cell
treatment (Fig. 3 A, B, Table 3).
Histology and correlation with MRI
Basic H&E histology was performed to determine if changes in T2-relaxation times, ADC-
values and volume of hyperintense signals correlate with the successful destruction of
glioblastoma. The region with increased T2-values one day post specific T-cell introduction
(Fig. 1) matched closely with the area of highly reduced cell density on H&E (Fig. 4 A,
arrowhead). In contrast, reduced cell density was not observed for animals treated with non-
specific T-cells or PBS (Fig. 4 B, C). The same area of reduced cell density in H&E stained
slides had increased ADC values two and three days post IL13Rα2 T-cells treatment (Fig. 2
and Fig. 4 A). On T1-weighted images 1 day following IL13Rα2 T-cell injection, a region with
strongly enhanced signal could be noted upon visual inspection. This region had significantly
increased signal intensity (two sample t-test, p<0.05) compared to the remaining ipsilateral
glioblastoma, 1.43±0.19 vs. 1.13±0.13, (Fig. 3 A). Signal intensities were normalized to signal
intensity in the contralateral glioblastoma. The strongly enhanced region matched very closely
the area of glioblastoma regression identified with H&E histology (Fig. 4 A).
To determine the penetration and trafficking of T-cells within the glioblastoma three days
following IL13Rα2 or non-specific T-cell injection we used pan-leukocyte marker CD45. T-
cells were distributed throughout the tumor for both T-cell types (Fig. 4 D, E). In both cases,
T-cells penetrated into the glioblastoma, but did not migrate to the contralateral side (data not
shown). However, in the case of non-specific T-cell there was no sign of cytolysis (Fig. 4 E).
DISCUSSION
Several phases of interaction between IL13Rα2 T-cells and glioblastoma cells were revealed
by distinct changes observed using multimodal MRI. The initial phase is activation of the
antitumor effector function of IL13Rα2 T-cells upon encountering IL13Rα2 positive
glioblastoma cells, which occurs within the first 24 h. The earliest detectable changes in this
phase are increased T2-relaxation times and strongly enhancing areas present on the T1-
weighted post contrast images. In the second, lytic phase, massive glioblastoma cell death
begins to take place, indicated by an increase in ADC values. In the third, silencing phase,
appearance of antigen-specific unresponsive IL13Rα2 T-cells is indicated by a diminished
hyper enhancing area in T1-weighted images, return of T2-relaxation times to pretreatment
values, and continued elevation of ADC values.
Increased T2-relaxation time indicates presence of antigen reactive T-cells
The initial increase in T2-relaxation times likely represents strong inflammatory response
triggered by specific T-cells encountering IL-13 antigen expressed by the glioblastoma. Similar
regional increases in signal intensity on T2-weighted images were previously reported in animal
models of multiple sclerosis (26). Following injection of T-cells specific for myelin basic
protein (MBP), areas of the white matter with increased T2-signal were observed, with the
T2-signal changes attributed to intense inflammation and edema (26). Supporting the
hypothesis of strong inflammatory response, one day following application of IL13Rα2 T-
cells, is the appearance of an area with strongly enhanced signal intensity on post contrast T1-
weighted image, overlapping with the area of increased T2-relaxation time. The enhanced
regions of white matter on T1-weighted images following contrast agent injections were also
reported for animals injected with T-cells specific for MBP (26). The area with strongly
enhanced signal intensity found one day following i.c. IL13Rα2 T-cells is likely the site of
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initial antigen reactive IL13Rα2 T-cells, since it overlaps three days later with the area void of
contrast enhancement and the area where glioblastoma regression was noted upon histology.
All animals injected with IL13Rα2 T-cells exhibited markedly enhancing white matter tracts
on the T2-weighted image in the ipsilateral hemisphere one day following the injection (Fig.
1). Because this was accompanied by increased ADC values at the same time point, we
conclude that this enhancement is due to increased interstitial fluid (brought about by
inflammation and edema) along the fibers of the external capsule. The rapid and preferential
movement of interstitial fluid along white matter tracts has been reported in rats injected with
Evans blue into the frontal region at the grey-white matter junction (27). Increased interstitial
fluid may also be a result of glioblastoma cell lysis. However, this is less likely since two days
following IL13Rα2 T-cells i.c. injection when ADC become significantly increased, the T2-
enhancement of external capsule is less prominent.
The relatively fast decrease in T2-relaxation times at two and three days following the injection
of IL13R□2 T-cells can be attributed to a slow decline in cytotoxic action of T-cells.
Alternatively, magnetic susceptibility effects of hemosiderin resulting from the injection may
contribute to the reduction of T2-relaxation times. A general trend toward shortening of T2-
relaxation times observed in control animals injected with non-specific T-cells and PBS at two
and three days post injection supports this explanation. In contrast, a statistically significant
decrease of T2-relaxation times in the contralateral glioblastoma of the animals injected with
IL13R□2 T-cells, at 1-3 days post injection, is a surprising result, and probably reflects decrease
in the glioblastoma extracellular water content, where the exact mechanism is yet to be
determined.
Increased ADC, evidence of successful glioblastoma lysis
In accordance with previous studies that used DWI and ADC as markers of therapeutic response
in humans and animal models (5-9), we have found good correspondence between tumor
regions with increased ADC values and the area of glioblastoma regression identified upon
histology. In a recent study utilizing genetically engineered nestin tv-a (Ntv-a) mice, where
low and high grade gliomas are developed following infection with ALV-A expressing platelet-
derived growth factor (10), increased ADC well correlated with lower grade gliomas, and initial
decreased cellularity following temozolomide treatment. A significant increase in ADC was
previously reported as early as 24 h following introduction of 1,3-bis(2-chloroethyl)-1-
nitrosourea in the rat glioma model (5). While, in this study we observed increased T2-
relaxation times at 24 h i.c. and the earliest detectable increase in ADC was two days following
i.c. IL13Rα2 T-cell injection. The difference may be attributed to initial cytotoxic action of T-
cells, leading to cytotoxic edema (of glioblastoma cells) and resulting in decreased ADC values.
It is possible, however, that the presence of vasogenic edema (noticed as increased T2-
relaxation time, and usually accompanied with increased ADC values) outweighs the effect of
cytotoxic edema (reduced ADC values). The simultaneous presence of vasogenic and cytotoxic
edema leading to pseudo-normal ADC values has been previously noted in ischemic stroke
(28).
Decreased area of signal enhancement on T1-weighted imaging, beginning of the silencing
phase?
The presence of scattered T-cells throughout the tumor was noticed upon histologic
examination. However, except for the area that had enhanced MRI signal intensity one day
following specific T-cell injection, there was no sign of glioblastoma cytolysis. One possible
explanation is antigen-specific T-cell anergy. Rapid development (within six days) of antigen
specific anergic T-cells has been observed following specific T-cell adoptive transfer into
tumor-bearing host (29). In addition the absence of co-stimulatory factors such as IL-2 may
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further accelerate this process (30). A slow decline in cytotoxic activity is further supported
by reduction in contrast enhancement, three days following specific T-cell injection.
IL13Rα2 T-cells, MRI and implication for the human studies
Currently, several strategies that employ specific targeting of IL13Rα2 to glioblastoma cells
have entered the first or second phase of clinical evaluation (21,31-33). The feasibility and
tolerability of IL13Rα2 T-cells are being evaluated in a Food and Drug Administration-
authorized pilot study (BB IND#10109). The goal of the pilot study is to evaluate efficacy of
IL13Rα2 T-cells delivered to tumor resection cavity following surgery. The main challenge,
however, will be development of cytolytic T-cells equipped with factors that can enhance
survival and prolong the effector functions in the glioma microenvironment. Development of
efficacious methods to monitor tumor response in vivo over time will significantly enhance
these efforts.
CONCLUSIONS
The ability to predict outcome early in the treatment regime is always desirable, especially
with aggressive tumor such as glioblastoma multiforme. Elevated T2-values at one day, and
increased ADC-values at two and three days following IL13Rα2 T-cell injection correlate well
with successful cytolytic destruction of glioblastoma by IL13Rα2 expressing T-cells evident
on histology. In addition the full or partial restoration of BBB integrity following IL13Rα2 T-
cell application is an important MRI indicator of tumor regression. Taken together these
indicators provide a powerful measure of tumor response to treatment that can be easily
performed in clinical settings to aid better prognosis. In conclusion, longitudinal MRI
monitoring provides spatial and temporal discrimination in response of glioblastoma
multiforme to IL13Rα2 T-cells in a mouse model system, and aids in establishing early the
efficacy of treatment.
Acknowledgements
The authors wish to acknowledge support of the Gordon and Betty Moore Foundation to the Caltech Brain Imaging
Center, NIH R01 EB000993 (R.E.J.), NIH 1F32NS058164-01 (J. L.), and National Center for Research Resources
Grant U24 RR021760 entitled Mouse BIRN (R.E.J.).
REFERENCES
1. Liu A, Guardino A, Chinsangaram L, Goldstein MJ, Panicali D, Levy R. Therapeutic vaccination
against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40
ligand. Cancer Res 2007;67:7037–44. [PubMed: 17638917]
2. Porta C, Paglino C, Imarisio I, Bonomi L. Cytokine-based immunotherapy for advanced kidney cancer:
past results and future perspectives in the era of molecularly targeted agents. ScientificWorldJournal
2007;7:837–49. [PubMed: 17619768]
3. Sabbatini P, Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol
2007;25:2884–93. [PubMed: 17617519]
4. Walden P. Therapeutic vaccination for the treatment of malignant melanoma. Recent Results Cancer
Res 2007;176:219–27. [PubMed: 17607929]
5. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic
resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10:7852–9. [PubMed:
15585617]
6. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to
therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457–66. [PubMed:
9815831]
Lazovic et al. Page 8













7. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate
marker of therapeutic efficacy in brain tumors. Journal of the National Cancer Institute 2000;92:2029–
36. [PubMed: 11121466]
8. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant
breast cancer chemotherapy. Clin Cancer Res 2007;13:443–50. [PubMed: 17255264]
9. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor
xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic
resonance imaging. Neoplasia (New York, N.Y 1999;1:113–7.
10. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of
tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Clin Cancer Res 2007;13:2897–904. [PubMed: 17504989]
11. Di Costanzo A, Trojsi F, Giannatempo GM, et al. Spectroscopic, diffusion and perfusion magnetic
resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results. J Exp Clin
Cancer Res 2006;25:383–90. [PubMed: 17167979]
12. Hayashida Y, Hirai T, Morishita S, et al. Diffusion-weighted imaging of metastatic brain tumors:
comparison with histologic type and tumor cellularity. Ajnr 2006;27:1419–25. [PubMed: 16908550]
13. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain
tumor patients using diffusion-weighted magnetic resonance imaging. Cancer research
2001;61:4971–3. [PubMed: 11431326]
14. Mardor Y, Roth Y, Ochershvilli A, et al. Pretreatment prediction of brain tumors’ response to radiation
therapy using high b-value diffusion-weighted MRI. Neoplasia (New York, N.Y 2004;6:136–42.
15. Cao Y, Nagesh V, Hamstra D, et al. The extent and severity of vascular leakage as evidence of tumor
aggressiveness in high-grade gliomas. Cancer research 2006;66:8912–7. [PubMed: 16951209]
16. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme:
predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative
cerebral blood volume. J Magn Reson Imaging 2004;19:546–54. [PubMed: 15112303]
17. Leimgruber A, Ostermann S, Yeon EJ, et al. Perfusion and diffusion MRI of glioblastoma progression
in a four-year prospective temozolomide clinical trial. International journal of radiation oncology,
biology, physics 2006;64:869–75.
18. Valonen PK, Lehtimaki KK, Vaisanen TH, et al. Water diffusion in a rat glioma during ganciclovir-
thymidine kinase gene therapy-induced programmed cell death in vivo: correlation with cell density.
J Magn Reson Imaging 2004;19:389–96. [PubMed: 15065161]
19. Lazovic J, Basu A, Lin HW, et al. Neuroinflammation and both cytotoxic and vasogenic edema are
reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke; a journal
of cerebral circulation 2005;36:2226–31. [PubMed: 16179572]
20. Oh J, Cha S, Aiken AH, et al. Quantitative apparent diffusion coefficients and T2 relaxation times in
characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson
Imaging 2005;21:701–8. [PubMed: 15906339]
21. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and
killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer
Res 2004;64:9160–6. [PubMed: 15604287]
22. Cooper LJ, Kalos M, DiGiusto D, et al. T-cell genetic modification for re-directed tumor recognition.
Cancer Chemother Biol Response Modif 2005;22:293–324. [PubMed: 16110618]
23. Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol
Ther 2000;1:49–55. [PubMed: 10933911]
24. Schmithorst VJ, Dardzinski BJ, Holland SK. Simultaneous correction of ghost and geometric
distortion artifacts in EPI using a multiecho reference scan. Ieee 2001;Trans Med Imaging 20:535–
9.
25. Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture.
Neuroimaging clinics of North America 2006;16:619–32. viii–ix. [PubMed: 17148023]
26. Namer IJ, Steibel J, Poulet P, et al. Blood-brain barrier breakdown in MBP-specific T cell induced
experimental allergic encephalomyelitis. A quantitative in vivo MRI study. Brain 1993;116(Pt 1):
147–59. [PubMed: 7680933]
Lazovic et al. Page 9













27. Geer CP, Grossman SA. Interstitial fluid flow along white matter tracts: a potentially important
mechanism for the dissemination of primary brain tumors. Journal of neuro-oncology 1997;32:193–
201. [PubMed: 9049880]
28. Ironside, J.; Pickard, J. Raised intracranial pressure, oedema and hydrocephalus. In: Greenfield, JG.;
Graham, DI.; Lantos, PL., editors. Greenfield’s neuropathology. Vol. 7th ed.. Arnold; London: 2002.
29. Staveley-O’Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy:
An early event in the course of tumor progression. Proceedings of the National Academy of Sciences
of the United States of America 1998;95:1178–83. [PubMed: 9448305]
30. Schwartz RH. T cell anergy. Annual review of immunology 2003;21:305–34.
31. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from
bench to bedside. Journal of neuro-oncology 2003;65:37–48. [PubMed: 14649884]
32. Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK. Evidence that IL-13R alpha2 chain in human
glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
J Immunother 2005;28:193–202. [PubMed: 15838375]
33. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Convection-enhanced delivery of interleukin-13
receptor-directed cytotoxin for malignant glioma therapy. Technology in cancer research & treatment
2006;5:239–50. [PubMed: 16700620]
Lazovic et al. Page 10













Figure 1. (A-C) Evolution of T2-weighted signal intensity following IL13Rα2 T-cells, non-specific
T-cells, PBS and corresponding T2-histograms (D-F)
A single coronal slice of one animal is shown one day prior to treatment and 1-3 days post
treatment. Brain slices shown correspond to the level of the anterior commissure. As a
consequence of IL13Rα2 T-cell adoptive transfer, increased signal intensity (arrowhead) is
observed in the tumor and the external capsule (A). No significant changes were present in
animals treated with non-specific T-cells and PBS (B, C). A black circle shows a typical region
of interest used for calculating mean T2-relaxation time and T2-histogram distributions.
T2-histograms were calculated from a single representative slice using the region of interest
from T1-weighted images, and averaged across animals in the each treatment group. One day
post i.c. IL13Rα2 T-cell injection, the T2-histogram distribution changes significantly from
the distribution prior to treatment with more pixels having increased T2-relaxation times (D).
Animals injected with non-specific T-cells had significantly more pixels with shorter T2-
relaxation times (E), at 1-2 days post treatment. No significant changes in T2-histogram
distribution were present with PBS treatment (F). Two-sample Kolmogorov-Smirnov test, *
p<0.001.
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Figure 2. (A-C) Evolution of apparent diffusion coefficient (ADC) following IL13Rα2 T-cells, non-
specific T-cells, PBS, and corresponding ADC-histograms (D-F)
A single coronal slice matching the slice position of the T2-weighted images is shown for one
animal at one day prior to and at one, two and three days post corresponding treatment. The
ADC values within the glioblastoma became significantly increased at two and three days
following IL13Rα2 T-cell adoptive transfer (A). There was no significant increase in ADC
values following non-specific T-cell or PBS treatment (B, C). Yellow circle shows a typical
region of interest used for calculating mean ADC-values and ADC-histogram distribution.
A significant change in ADC-histogram distribution was only present for IL13Rα2 T-cell
treated group (D) two and three days post treatment. There were no changes in ADC-histogram
distribution for non-specific T-cell (E) or PBS (F) treated animals. Two-sample Kolmogorov-
Smirnov test, * p<0.001.
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Figure 3. (A-C) Evolution of T1-weighted signal intensity (post contrast) and (D) changes in volume
of the signal enhancement, following IL13Rα2 T-cells, non-specific T-cells, PBS
A single coronal slice matching the slice position of the T2-weighted and ADC images is shown
for same animal at one day prior to and at one, and three days post corresponding treatment.
Notice a glioblastoma region with significantly increased T1-weighted signal intensity
(arrowhead) at one day following IL13Rα2 T-cell i.c. injection (A). The enhanced signal
intensity was not present in this region, three days following IL13Rα2 T-cell injection,
indicating glioblastoma regression. There was no significant change in T1-weighted post
contrast signal intensity for animals treated with non-specific T-cell or PBS (B, C). Black circle
shows the example of region of interest used for calculating mean signal intensity. A dotted
line divides glioblastoma region within strongly enhancing signal intensity from the remaining
enhancing area.
(D) All volumes were normalized to the corresponding mean volume one day prior to treatment
and expressed as percentage ± SEM of the pretreatment mean volume. ANOVA with repeated
measures, with Holm-Sidak correction for multiple pair-wise comparison, * p<0.05.
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Figure 4. Glioblastoma tumor histology. Hematoxylin and eosin staining of coronal sections
corresponding to similar planes of interest in MR images and ADC maps (A-C) and CD-45 staining
(D, E)
Ipsilateral side showing glioblastoma regression (arrowhead) in mice treated with IL13Rα2 T-
cell (A). Corresponding section of glioblastoma found on ipsilateral side in mice treated with
non-specific T-cell (B), and PBS (C) treated mice. Ipsilateral glioblastoma were infiltrated with
IL13Rα2 T-cell (D) and non-specific T-cells (E). Scale bar represents 400 μm (A-C), and 200
μm (D, E).
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Table 1
Mean T2-relaxation times for whole tumor volume for different treatment groups and days. Average T2-values within
ipsilateral volumes were calculated for each animal before and compared with after treatment values. The same was
done for the contralateral tumor volumes. ANOVA with repeated measures followed by Holm-Sidak post-hoc test was
used to determine if the differences in the mean T2-values among different days of treatment are greater than the
differences due to random sampling variability. Results are shown as mean±SD
T2 [ms] -1 day +1 day +2 days +3 days
IL13Rα2 T-cells (ipsilateral) 48.5±2.8 52.5±2.3 * 50.5±2.7 49.3±2.1
Non-specific T-cells (ipsilateral) 49.8±1.3 48.6±1.9 46.8±2.9 46.0±3.1
PBS (ipsilateral) 48.6±1.1 47.0±2.9 47.0±3.0 47.2±2.6
IL13Rα2 T-cells (contralateral) 49.3±1.6 47.0±2.0* 45.7±1.9* 45.3±2.3*
Non-specific T-cells (contralateral) 48.6±1.5 47.8±2.4 45.6±4.2 45.4±3.3
PBS (contralateral) 46.7±1.3 48.0±3.5 46.2±3.0 47.5±2.1
*
p<0.05, data is given as mean±SD
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Table 2
Mean ADC-values for whole tumor volume for different treatment groups and days. Average ADC-values within
ipsilateral tumor volumes were calculated for each animal before and compared with after treatment values. The same
was done for contralateral tumor volumes. ANOVA with repeated measures followed by Holm-Sidak post-hoc test
was used to determine if the differences in the mean ADC-values among different days of treatment are greater than
the differences due to random sampling variability. Results are shown as mean±SD
ADC [10-3mm2/s] -1 day +1 day +2 days +3 days
IL13Rα2 T-cells (ipsilateral) 7.4±0.6 8.4±0.6 9.4±1.5 * 9.7±1.2 *
Non-specific T-cells (ipsilateral) 7.2±0.4 7.5±0.3 7.3±0.7 7.0±0.6
PBS (ipsilateral) 6.9±0.3 7.3±0.9 7.2±0.9 7.1±0.7
IL13Rα2 T-cells (contralateral) 7.1±0.7 7.3±0.7 7.2±0.8 6.8±0.6
Non-specific T-cells (contralateral) 7.9±0.8 7.7±0.6 7.5±0.3 6.7±0.3
PBS (contralateral) 6.8±0.5 7.4±1.1 7.1±0.6 7.4±1.3
*
p<0.05, data is given as mean±SD
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Table 3
Mean tumor volume for different treatment groups and days. Ipsilateral tumor volumes were calculated for each animal
before and compared to after treatment volumes. The same was done for contralateral tumor volumes. ANOVA with
repeated measures followed by Holm-Sidak post-hoc test was used to compare the mean tumor volumes among same
treatment group for different days. Results are shown as mean±SD
T1-signal volumes [mm
3] -1 day +1 day +3 days
IL13Rα2 T-cells (ipsilateral) 2.82±1.77 3.57±2.17 1.32±1.30*
Non-specific T-cells (ipsilateral) 2.26±0.76 3.68±1.40 2.76±0.67
PBS (ipsilateral) 1.67±0.69 2.51±1.06 2.52±0.92
IL13Rα2 T-cells (contralateral) 2.17±0.87 1.57±0.80 2.11±0.77
Non-specific T-cells (contralateral) 2.23±0.37 2.33±0.97 2.08±0.73
PBS (contralateral) 1.34±0.67 1.89±1.14 2.02±1.07
*
p<0.05, data is given as mean±SD
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